Calithera Biosciences, Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (20)

View All

Latest Posts

About This Stock More About This Stock
A Perspective On The Upcoming Calithera Cystic Fibrosis Read-Out
Article By: Scott Matusow
Monday, August 2, 2021 8:59 PM EDT
Calithera is guiding for the market to expect what we believe will be a key data read-out in Q3 from its ongoing CB-280 study involving Cystic Fibrosis. A positive read-out here could see a significant upside for the company stock.
In this article: CALA, VRTX Also: INCY
Read
Calithera Biosciences: An Under The Radar Opportunity
Article By: Scott Matusow
Monday, December 7, 2020 5:30 AM EDT
Calithera is a high-risk, high reward speculative investment addressing high unmet and under-served needs markets, with a lower bar data threshold to meet. Calithera has an important near-term catalyst shortly upcoming.
In this article: PFE, TRIL, EXEL, CALA Also: BMY, MRK, ESALF, GILD
Read
2 Names To Consider In A Heating Up Small-Cap Biotech Sector
Article By: Scott Matusow
Wednesday, November 27, 2019 8:30 AM EDT
The biotech sector has been heating up due to an increased risk appetite coming from additional market liquidity and a favorable Fed policy. Here, we highlight 2 early-stage biotech companies that we think can provide substantial upside.
In this article: CALA, CRIS Also: INCY, PFE, AZN, CNST, KRTX, NXTC
Read
Calithera Bioscience Shares Surge After Fast Track Designation Status
Article By: TickerTV
Wednesday, April 18, 2018 3:40 PM EDT
Shares of Calithera Biosciences, Inc. gained $0.60, or $9.45% during premarket trade on Wednesday.
In this article: CALA
Read
Calithera Pharma In Focus, Part 3 - Arginase Inhibitor And Acquisition Target
Article By: Scott Matusow
Monday, January 9, 2017 7:51 AM EDT
In the last part of our series on Calithera Biosciences we will be examining the company's second clinical asset and its acquisition chances sometime this year or early 2018.
In this article: CALA Also: GILD, BMY, AMGN, FPRX, AFMD
Read
All Posts

Latest Tweets for $CALA

No tweets yet!

PARTNER HEADLINES

$CALA

Comments Status Updates
Calithera Biosciences: An Under The Radar Opportunity
Anne Davis • 12/7/2020 10:50:51 AM

$CALA sounds like a good buy.

1 to 1 of 1 comments